Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study ... 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage ...
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Veru Veru’s oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health. In a mid-stage study, patients who received the drug along with Wegovy ...
Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified ... 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late ...
Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...
MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key ...
Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback